Document Detail

Effective use of TNF antagonists.
MedLine Citation:
PMID:  15228618     Owner:  NLM     Status:  MEDLINE    
Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved functional outcomes in patients with rheumatoid arthritis (RA). RA is a progressive disease in which structural joint damage can continue to develop even in the face of symptomatic relief. Before the introduction of biologic agents, the management of RA involved the use of disease-modifying antirheumatic drugs (DMARDs) early in the course of disease. This focus on early treatment, combined with the availability of the anti-TNF agents, has contributed to a shift in treatment paradigms favoring the early and timely use of DMARDs with biologic therapies. Improvement in symptom control does not always equate to a reduction in disease progression or disability. With the emergence of structure-related outcome measures as the primary means for assessing the effectiveness of antirheumatic agents, the regular use of X-rays is recommended for the continued monitoring and evaluation of patients. In addition to the control of symptoms and improvement in physical function, a reduction in erosions and joint-space narrowing should be considered among the goals of therapy, leading to a better quality of life. Adherence to therapy is an important element in optimizing outcomes. Durability of therapy with anti-TNF agents as reported from clinical trials can also be achieved in the clinical setting. Concomitant methotrexate therapy might be important in maintaining TNF antagonist therapy in the long term. Overall, the TNF antagonists have led to improvements in clinical and radiographic outcomes in patients with RA, especially those who have failed to show a complete response to methotrexate.
David Yocum
Related Documents :
20621538 - Outcome and safety of tnfα antagonist therapy in 475 consecutive outpatients (with rh...
18189188 - Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in...
17023748 - Association between recurrent aphthous stomatitis and salivary thiocyanate levels.
23328738 - Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline...
3534198 - Glycine-based oral rehydration solution: reassessment of safety and efficacy.
24433388 - Pulse in pulse intense pulsed light for melasma treatment: a pilot study.
Publication Detail:
Type:  Journal Article; Review     Date:  2004-06-21
Journal Detail:
Title:  Arthritis research & therapy     Volume:  6 Suppl 2     ISSN:  1478-6362     ISO Abbreviation:  Arthritis Res. Ther.     Publication Date:  2004  
Date Detail:
Created Date:  2004-07-01     Completed Date:  2005-10-03     Revised Date:  2010-09-20    
Medline Journal Info:
Nlm Unique ID:  101154438     Medline TA:  Arthritis Res Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  S24-30     Citation Subset:  IM    
University of Arizona Arthritis Center, Tucson, AZ, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Reg. No./Substance:
0/Antirheumatic Agents; 0/Tumor Necrosis Factor-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Does route of administration affect the outcome of TNF antagonist therapy?
Next Document:  Treating psoriatic arthritis: how effective are TNF antagonists?